Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …

RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M).

Mosquirix provides short-term protection that could potentially save lives in the age group most at risk from malaria. The main study of Mosquirix showed that the vaccine can prevent malaria in …

RTS,S/AS01 (brand name Mosquirix) [1] is the first malaria vaccine approved for public use. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for …

RTS,S/AS01 (Mosquirix ®) is a vaccine against malaria caused by Plasmodium falciparum. In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria …

Mosquirix is indicated for active immunisation of children aged 6 weeks up to 17 months against malaria caused by Plasmodium falciparum and against hepatitis B (see sections 4.2, 4.4 and …

Apr 2, 2024 · Develop and license malaria vaccines with protective efficacy of at least 75% against clinical malaria for areas with ongoing malaria transmission.

Sep 6, 2022 · GSK plc (LSE/NYSE: GSK) announced today that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s …

Mar 3, 2020 · As this concerning trend calls for new tools to combat the disease, the RTS,S vaccine has arrived just in time. The vaccine was created in 1987 and began pilot …

In October 2021, the World Health Organization (WHO) recommended a malaria vaccine for children living in areas where malaria is common. This is the world’s first malaria vaccine. The …